I share the same sentiment around the financial results: increased revenue was predominantly a single milestone cash flow. Removing this as a one off cash flow, losses were more around the 10m mark for the quarter, and the increase in revenue royalties and declining costs of trials and studies is relatively immaterial and most likely cyclical in nature. Future partnerships and progress with stage 3 and fda approvals will be key, but generally things are looking better little by little.
I share the same sentiment around the financial results:...
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |